A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

Description

This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.

Conditions

Multiple Myeloma

Talk to us

Study Overview

On this page

Study Details

Study overview

This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.

Prospective Multi-Center Study to Identify Barriers to Cellular Therapies in Patients With Plasma Cell Disorders PROACT PCD

A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

Condition
Multiple Myeloma
Intervention / Treatment

-

Contacts and Locations

Basking Ridge

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States, 07920

Middletown

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States, 07748

Montvale

Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States, 07645

Commack

Memorial Sloan Kettering Commack, Commack, New York, United States, 11725

Harrison

Memorial Sloan Kettering Westchester, Harrison, New York, United States, 10604

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Uniondale

Memorial Sloan Kettering Nassau, Uniondale, New York, United States, 11553

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of Multiple Myeloma after January 1, 2017.
  • * Karnofsky Performance Status \> 70%
  • * ≥ 2 lines of prior therapy
  • * Anticipated to start new a line of therapy for RRMM within the next 12 months
  • * Age 18-80 years of age.
  • * English or Spanish speaking.
  • * Willing to provide informed consent
  • * Willing to perform study procedures.
  • * Be a Co-Investigator
  • * Agree to comply with study procedures
  • * Active CNS disease
  • * Patients who already have a definitive plan are to be excluded

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Heather Landau, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2029-05-03